Сравнение

Amycretin vs. VK2735

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Метаболизм

Номер CAS

нет данных

Молекулярная масса

нет данных

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Amycretin

Amycretin activates both the GLP-1 and the amylin receptor in a single molecule. Both pathways independently suppress appetite and food intake — the combination is intended to amplify the effect beyond the GLP-1 axis alone.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Amycretin	VK2735
Германия	Не одобрено	Не одобрено
США	Не одобрено	Не одобрено

Полные записи

Frequently asked questions

What is the difference between Amycretin and VK2735?: Amycretin is classified as "Метаболизм", while VK2735 is classified as "Метаболизм". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Amycretin or VK2735?: The highest available evidence level is "РКИ на людях" for Amycretin and "РКИ на людях" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Amycretin and VK2735 in Germany and the United States?: Германия: Amycretin — Не одобрено, VK2735 — Не одобрено. США: Amycretin — Не одобрено, VK2735 — Не одобрено. These are factual summaries with source and review date on the individual pages.

Country

Amycretin

VK2735

Германия

Не одобрено

США

Не одобрено

Frequently asked questions

What is the difference between Amycretin and VK2735?

Amycretin is classified as "Метаболизм", while VK2735 is classified as "Метаболизм". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Amycretin or VK2735?

The highest available evidence level is "РКИ на людях" for Amycretin and "РКИ на людях" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Amycretin and VK2735 in Germany and the United States?

Германия: Amycretin — Не одобрено, VK2735 — Не одобрено. США: Amycretin — Не одобрено, VK2735 — Не одобрено. These are factual summaries with source and review date on the individual pages.